Publications by authors named "James Chih-Hsin Yang"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

83

Total Likes

183

Extended Reach

769,580

Social Features

96
H
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Helena A Yu, Yasushi Goto, Hidetoshi Hayashi, Enriqueta Felip, James Chih-Hsin Yang, Martin Reck, Kiyotaka Yoh, Se-Hoon Lee, Luis Paz-Ares, Benjamin Besse

J Clin Oncol· December 2023

Videos about Article: user

1 2 95 1 18

View All Article and Social Media Activity
A
Amivantamab Plus Lazertinib in Atypical -Mutated Advanced Non-Small Cell Lung Cancer: Results From CHRYSALIS-2.
Pascale Tomasini, Yongsheng Wang, Yongsheng Li, Enriqueta Felip, Lin Wu, James Chih-Hsin Yang

J Clin Oncol· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns and subsequent treatment effectiveness following frontline brigatinib in the ALTA-1L trial.
Myung-Ju Ahn, Angelo Delmonte, Sharmistha Ghosh, Maximilian Hochmair, Tsung-Ying Yang, James Chih-Hsin Yang

Future Oncol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Se-Hoon Lee, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira, James Chih-Hsin Yang

J Thorac Oncol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MAGELLAN arms B1 and B3: Durvalumab plus chemotherapy with and without oleclumab in treatment-naïve metastatic non-small-cell lung cancer.
Byoung Chul Cho, Chaiyut Charoentum, Dong-Wan Kim, Cheng-Ta Yang, Rafal Dziadziuszko, James Chih-Hsin Yang

Lung Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).
James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet, Yun Fan, Dongqing Lv, Tsung-Ying Yang

J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
James Chih-Hsin Yang, Shun Lu, Hidetoshi Hayashi, Enriqueta Felip, Alexander I Spira

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With Fusion-Positive NSCLC: A LIBRETTO-431 Subgroup Analysis.
Koichi Goto, Herbert H Loong, Caicun Zhou, Kazumi Nishino, Dae Ho Lee, James Chih-Hsin Yang

JTO Clin Res Rep· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PD-L1 regulates c-MET phosphorylation and contributes to MET-dependent resistance to osimertinib in EGFR-mutant NSCLC.
Chia-Chi Hsu, Derek De-Rui Huang, Wei-Hsun Hsu, Min-Shu Hsieh, Fang-Yu Lin, James Chih-Hsin Yang

J Biomed Sci· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival with Osimertinib plus Chemotherapy in -Mutated Advanced NSCLC.
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, James Chih-Hsin Yang, Ying Liu

N Engl J Med· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial.
James Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, Kien Hung Do, Piyada Sitthideatphaiboon, Cheng-Ta Yang

Clin Lung Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab in Participants With Advanced NSCLC and MET Exon 14 Skipping Mutations: Final Results From the CHRYSALIS Study.
Matthew G Krebs, Byoung Chul Cho, Sandrine Hiret, Ji-Youn Han, Ki Hyeong Lee, James Chih-Hsin Yang, Siyang Qu

J Thorac Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to: Afatinib, Dose Reduction, and Pseudo-Acute Kidney Injury.
Derek De-Rui Huang, James Chih-Hsin Yang

J Clin Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.
Mariam Alexander, Ying Cheng, Se-Hoon Lee, Antonio Passaro, Alexander I Spira, James Chih-Hsin Yang

Eur J Cancer· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab.
Zofia Piotrowska, Antonio Passaro, Danny Nguyen, Gerrina Ruiter, Ross A Soo, James Chih-Hsin Yang, Zhihui Sunny Yang

J Clin Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Prognostic Role of Tertiary Lymphoid Structures and Immune Microenvironment Signatures in Early-Stage -Mutant Lung Adenocarcinoma.
Wei-Hsun Hsu, Chia-Chi Hsu, Min-Shu Hsieh, James Chih-Hsin Yang

Cancers (Basel)· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Derek De-Rui Huang, James Chih-Hsin Yang

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amivantamab plus lazertinib versus osimertinib as first-line treatment in EGFR-mutated advanced non-small cell lung cancer: MARIPOSA Asian subset.
Byoung Chul Cho, Hidetoshi Hayashi, Jong-Seok Lee, Se-Hoon Lee, Pongwut Danchaivijitr, James Chih-Hsin Yang

Lung Cancer· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum: Every Patient Is Unique and Deserves the Best: The Present and Future Treatment Landscape of Uncommon Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer.
Derek De-Rui Huang, James Chih-Hsin Yang

J Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation.
Yan Xu, James Chih-Hsin Yang, Yanqiu Zhao, Ludovic Doucet, Jianying Zhou, Runxiang Yang

Cell Rep Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.
David Planchard, Pasi A Jänne, Ying Cheng, James Chih-Hsin Yang, Noriko Yanagitani

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A plain language summary of results from the FLAURA2 study: Effects of initial (first-line) osimertinib plus chemotherapy on the brain in patients with EGFR-mutated advanced non-small cell lung cancer.
Pasi A Jänne, David Planchard, Kunihiko Kobayashi, Ying Cheng, Chee Khoon Lee, Tsung-Ying Yang, James Chih-Hsin Yang

Future Oncol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study.
Hsin-Yi Wang, Wei-Yu Liao, Chao-Chi Ho, Shang-Gin Wu, Ching-Yao Yang, James Chih-Hsin Yang

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durvalumab, Tremelimumab, and Platinum Chemotherapy in Mutation-Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE).
Chee Khoon Lee, Bin-Chi Liao, Shalini Subramaniam, Chao-Hua Chiu, Antony J Mersiades, Tsung-Ying Yang, James Chih-Hsin Yang

JTO Clin Res Rep· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Alexander Spira, Byoung Chul Cho, Enriqueta Felip, Edward B Garon, Koichi Goto, James Chih-Hsin Yang

Lung Cancer· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors.
Yen-Lin Huang, Chia-Chi Hsu, Derek De-Rui Huang, James Chih-Hsin Yang, Shang-Gin Wu

J Formos Med Assoc· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis